Articles related to FDA

Discover how the FDA-approved Invitae’s Common Hereditary Cancers Panel can enhance your approach to early cancer detection and personalized treatment planning.

The FDA’s recent concerns about NurOwn’s efficacy and manufacturing consistency could have far-reaching implications for the future of ALS treatment. Stay updated as the agency’s final decision is expected in December.

Ulotaront’s failure to meet its primary endpoint in recent phase 3 trials raises questions about the drug’s future and emphasizes the need for more effective treatments in the field of schizophrenia.

Discover how Exxua, the newly FDA-approved antidepressant, could be a game-changer in treating major depressive disorder, backed by robust clinical trials and a manageable side effect profile.

The FDA’s approval of brexpiprazole for Alzheimer’s-related agitation has sparked a debate over its efficacy and safety, raising concerns that extend beyond this specific drug to the integrity of the regulatory process itself.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.